Department of Biotechnology, AVIT, Vinayaka Missions University, Chennai, Tamilnadu, India.
Clin Nutr. 2011 Jun;30(3):351-8. doi: 10.1016/j.clnu.2010.11.005. Epub 2010 Dec 16.
BACKGROUND & AIMS: Recently, studies have reported that sesame oil lowered blood pressure and improved antioxidant status in hypertensive and diabetic-hypertensive patients. The aim of this study was to evaluate the effectiveness of sesame oil with anti-diabetic (glibenclamide) medication as combination therapy in mild-to moderate diabetic patients.
This open label study included sixty type 2 diabetes mellitus patients divided into 3 groups, receiving sesame oil (n = 18), 5 mg/day (single dose) of glibenclamide (n = 20), or their combination (n = 22). The patients were supplied with sesame oil [BNB Sesame oil(TM)] except glibenclamide group, and instructed to use approximately 35 g of oil/day/person for cooking, or salad preparation for 60 days. 12 h-fasting venous blood samples were collected at baseline (0 day) and after 60 days of the experiment for various biochemical analysis.
As compared with sesame oil and glibenclamide alone, combination therapy showed an improved anti-hyperglycemic effect with 36% reduction of glucose (P < 0.001 vs before treatment, P < 0.01 vs sesame oil monotherapy, P < 0.05 vs glibenclamide monotherapy) and 43% reduction of HbA(1c) (P < 0.001 vs before treatment, P < 0.01 vs sesame oil monotherapy, P < 0.05 vs glibenclamide monotherapy) at the end point. Significant reductions in the plasma TC, LDL-C and TG levels were noted in sesame oil (20%, 33.8% and 14% respectively vs before treatment) or combination therapies (22%, 38% and 15% respectively vs before treatment). Plasma HDL-C was significantly improved in sesame oil (15.7% vs before treatment) or combination therapies (17% before treatment). Significant (P < 0.001) improvement was observed in the activities of enzymatic and non-enzymatic antioxidants in patients treated with sesame oil and its combination with glibenclamide.
Sesame oil exhibited synergistic effect with glibenclamide and can provide a safe and effective option for the drug combination that may be very useful in clinical practice for the effective improvement of hyperglycemia.
最近的研究表明，芝麻油可以降低高血压和糖尿病合并高血压患者的血压，改善抗氧化状态。本研究旨在评估芝麻油与抗糖尿病药物（格列本脲）联合治疗轻度至中度糖尿病患者的疗效。
本开放标签研究纳入了 60 名 2 型糖尿病患者，分为 3 组，分别给予芝麻油（n = 18）、5mg/天（单次剂量）格列本脲（n = 20）或两者联合治疗（n = 22）。除格列本脲组外，患者均服用 BNB 芝麻油（TM），并指导其每天每人使用约 35g 油用于烹饪或沙拉制作，共 60 天。实验前（第 0 天）和 60 天后采集 12h 空腹静脉血样，进行各种生化分析。
与单独使用芝麻油和格列本脲相比，联合治疗组的降糖效果明显改善，血糖降低 36%（P < 0.001 与治疗前相比，P < 0.01 与单独使用芝麻油相比，P < 0.05 与单独使用格列本脲相比），HbA1c 降低 43%（P < 0.001 与治疗前相比，P < 0.01 与单独使用芝麻油相比，P < 0.05 与单独使用格列本脲相比）。治疗后，芝麻油（分别降低 20%、33.8%和 14%）或联合治疗（分别降低 22%、38%和 15%）可显著降低血浆 TC、LDL-C 和 TG 水平。芝麻油（15.7%与治疗前相比）或联合治疗（治疗前 17%）可显著提高血浆 HDL-C。联合治疗组患者的酶和非酶抗氧化剂活性均显著改善（P < 0.001）。
芝麻油与格列本脲具有协同作用，为联合用药提供了一种安全有效的选择，可能对临床实践中有效改善高血糖非常有用。
